Post-stroke conditions, vascular dementia (multi-infarct dementia), degenerative conditions associated with dementia (senile and presenile dementia of the Alzheimer’s type, dementia in Parkinson’s disease).
Composition and form of release
Sermion is made in the form of lyophilisate for preparation of solution for injection. The active ingredient of the drug is nicergoline 4 ml (4 mg).
Sermion is used in the treatment of acute and chronic cerebral vascular and metabolic disorders caused by atherosclerosis, arterial hypertension, thrombosis or cerebral vascular embolism, including dementia of vascular etiology, acute transient cerebrovascular accidents and circulatory disorders.
The drug is used in the treatment of acute and chronic peripheral vascular and metabolic disorders: Raynaud’s disease, functional and organic arteriopathies of the extremities, conditions caused by impaired peripheral blood flow.
In addition, Sermion is used in the complex treatment of hypertensive crises.
Acute bleeding, severe bradycardia, orthostatic hypotension, acute myocardial infarction, pregnancy and lactation period, intolerance to the components of the drug are considered absolute contraindications to the appointment of Sermion. In addition, Sermion tablets are not prescribed for patients with fructose intolerance, isomaltase or sucrase deficiency, glucose-galactose malabsorption, as well as for persons under 18 years of age.
A relative contraindication to the use of Sermion is gout, a history of hyperuricemia. So, care should be taken when prescribing a drug to patients who are taking drugs that cause metabolic disturbances and excretion of uric acid.
Application during pregnancy and lactation
The use of Sermion in the therapy of nursing and pregnant women is possible only in extreme cases, since the safety profile of nicergoline for this category of patients is unknown. The use of Sermion in the treatment of nursing and pregnant women is carried out only under strict medical supervision.
Method of administration and dosage
Sermion is administered intravenously, intramuscularly or intraarterially. The choice of the dosage regimen is based on the severity of the disease.
When administered intravenously, from 4 to 8 g of Sermion’s lyophilisate is dissolved in 0.9% sodium chloride solution or 5% dextrose solution. With intramuscular administration of the drug, the patient receives from 2 to 4 g of lyophilisate twice a day. With intra-arterial administration, the patient receives 4 mg of the drug, dissolved in 0.9% sodium chloride solution.
Even when Sermion is taken in doses significantly higher than therapeutic, patients do not have any negative symptoms, with the exception of a short-term decrease in arterial pressure.
When taking Sermion, the development of side effects is very rarely observed. Sometimes, with prolonged use of the drug, patients may experience a decrease in blood pressure, cold extremities, dizziness, weakness, sweating, dyspeptic disorders, increased acidity of gastric secretions, sleep disturbances and allergic skin reactions.
Storage conditions and periods
Sermion should be stored in dry places that are well protected from light penetration and are not accessible to small children. Shelf life of the lyophilized powder for injections is 4 years.